Juno Therapeutics (NASDAQ:JUNO) was downgraded by stock analysts at Guggenheim from a “buy” rating to a “neutral” rating in a note issued to investors on Monday, The Fly reports.
Several other equities research analysts also recently weighed in on JUNO. Raymond James Financial increased their price target on Juno Therapeutics from $45.00 to $61.00 and gave the stock an “outperform” rating in a report on Friday, November 3rd. Goldman Sachs Group reiterated a “neutral” rating and issued a $44.00 price target on shares of Juno Therapeutics in a report on Friday, October 6th. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Juno Therapeutics in a report on Thursday, January 11th. Wells Fargo & Co reiterated a “market perform” rating and issued a $63.00 price target (up from $54.00) on shares of Juno Therapeutics in a report on Wednesday, January 17th. Finally, Citigroup reiterated a “buy” rating and issued a $59.00 price target on shares of Juno Therapeutics in a report on Tuesday, October 31st. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $47.26.
Juno Therapeutics (JUNO) traded down $3.56 during trading hours on Monday, hitting $67.81. The stock had a trading volume of 5,229,600 shares, compared to its average volume of 4,292,823. The company has a market cap of $9,820.00, a price-to-earnings ratio of -20.00 and a beta of 2.32. Juno Therapeutics has a 1-year low of $19.07 and a 1-year high of $74.35. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77.
Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.07. The business had revenue of $44.80 million during the quarter, compared to analyst estimates of $18.12 million. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The company’s revenue for the quarter was up 115.4% on a year-over-year basis. During the same period last year, the company earned ($0.57) EPS. analysts expect that Juno Therapeutics will post -4.02 earnings per share for the current year.
In other news, EVP Robert Azelby sold 6,666 shares of the firm’s stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $54.95, for a total value of $366,296.70. Following the completion of the sale, the executive vice president now owns 79,998 shares of the company’s stock, valued at approximately $4,395,890.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Steve Harr sold 8,750 shares of the firm’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $44.76, for a total value of $391,650.00. Following the completion of the sale, the chief financial officer now directly owns 772,082 shares of the company’s stock, valued at approximately $34,558,390.32. The disclosure for this sale can be found here. Insiders sold a total of 365,337 shares of company stock worth $17,540,499 over the last quarter. Company insiders own 15.08% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. State of Alaska Department of Revenue acquired a new stake in shares of Juno Therapeutics in the 4th quarter worth $173,000. CAPROCK Group Inc. acquired a new stake in shares of Juno Therapeutics in the 4th quarter worth $260,000. Schwab Charles Investment Management Inc. boosted its position in shares of Juno Therapeutics by 16.6% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 378,195 shares of the biopharmaceutical company’s stock worth $17,288,000 after purchasing an additional 53,821 shares in the last quarter. California Public Employees Retirement System lifted its position in Juno Therapeutics by 2.7% during the 3rd quarter. California Public Employees Retirement System now owns 73,100 shares of the biopharmaceutical company’s stock worth $3,279,000 after acquiring an additional 1,900 shares during the period. Finally, Capital Bank & Trust Co acquired a new stake in Juno Therapeutics during the 3rd quarter worth about $8,517,000. 69.96% of the stock is owned by hedge funds and other institutional investors.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.